Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TT7EFHR)

• DTT Name: Corticotropin-releasing factor receptor 1 (CRHR1) DTT Info
• Gene Name: CRHR1

Molecule-Related Drug & Molecule List

1 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Telavancin	DM58VQX	Staphylococcus infection	1B5Y	Approved	[1]

6 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pexacerfont	DMBJ15R	Anxiety disorder	6B00-6B0Z	Phase 2/3	[2]
GSK561679	DMEVARK	Alcohol dependence	6C40.2	Phase 2	[3]
ONO-2333Ms	DMOT0WR	Anxiety disorder	6B00-6B0Z	Phase 2	[4]
SSR125543	DMGJEB8	Anxiety disorder	6B00-6B0Z	Phase 2	[5]
Tildacerfont	DMAB8LH	Congenital adrenal hyperplasia	5A71.01	Phase 2	[6]
GSK586529	DM5E9LX	Anxiety disorder	6B00-6B0Z	Phase 1	[3]

5 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CP-316,311	DMZ76EM	Major depressive disorder	6A70.3	Discontinued in Phase 2	[2]
GW876008	DMAXRBI	Irritable bowel syndrome	DD91.0	Discontinued in Phase 2	[2]
Antalarmin	DM2EKX5	Depression	6A70-6A7Z	Terminated	[7]
DMP-696	DMNSDM1	Anxiety disorder	6B00-6B0Z	Terminated	[8]
NBI-37582	DM3JY2N	Anxiety disorder	6B00-6B0Z	Terminated	[9]

1 Preclinical Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CRA1000	DMWMBIV	Anxiety disorder	6B00-6B0Z	Preclinical	[1]

8 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BMS-561388	DM3WBKN	Anxiety disorder	6B00-6B0Z	Investigative	[10]
CP-376395	DM93CA4	Discovery agent	N.A.	Investigative	[11]
CP154,526	DMYHR74	Depression	6A70-6A7Z	Investigative	[1]
Des-Arg(9)-[Leu(8)]-BK	DMVX9I0	Depression	6A70-6A7Z	Investigative	[1]
DMP-695/696	DMNRLA7	Depression	6A70-6A7Z	Investigative	[1]
N-mesityl-4,6-dimethyl-3-tosylpyridin-2-amine	DMI065U	Discovery agent	N.A.	Investigative	[12]
N-mesityl-6-methyl-3-tosylpyridin-2-amine	DMEUI8C	Discovery agent	N.A.	Investigative	[12]
PD-171729	DMJ3DOI	Discovery agent	N.A.	Investigative	[13]

References

• [1] A review of drug options in age-related macular degeneration therapy and potential new agents. Expert Opin Pharmacother. 2006 Dec;7(17):2355-68.
• [2] Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
• [3] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [4] Behavioral, biological, and chemical perspectives on targeting CRF(1) receptor antagonists to treat alcoholism. Drug Alcohol Depend. 2013 Mar 1;128(3):175-86.
• [5] Pharma & Vaccines. Product Development Pipeline. April 29 2009.
• [6] Clinical advances in the pharmacotherapy of congenital adrenal hyperplasia. Eur J Endocrinol. 2021 Nov 30;186(1):R1-R14.
• [7] Chronic administration of the non-peptide CRH type 1 receptor antagonist antalarmin does not blunt hypothalamic-pituitary-adrenal axis responses to acute immobilization stress. Life Sci. 1999;65(4):PL53-8.
• [8] In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists. J Med Chem. 2009 Jul 23;52(14):4161-72.
• [9] CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008.
• [10] 8-(4-Methoxyphenyl)pyrazolo[1,5-a]-1,3,5-triazines: selective and centrally active corticotropin-releasing factor receptor-1 (CRF1) antagonists. J Med Chem. 2009 May 14;52(9):3073-83.
• [11] 2-aryloxy-4-alkylaminopyridines: discovery of novel corticotropin-releasing factor 1 antagonists. J Med Chem. 2008 Mar 13;51(5):1385-92.
• [12] Synthesis and evaluation of 2-anilino-3-phenylsulfonyl-6-methylpyridines as corticotropin-releasing factor1 receptor ligands. Bioorg Med Chem Lett. 2006 Feb 15;16(4):934-7.
• [13] Pyrazolo[1,5-a]pyrimidine CRF-1 receptor antagonists. Bioorg Med Chem Lett. 1998 Aug 18;8(16):2067-70.